P68-4 Feasibility study of a new tissue-based comprehensive genome profiling test

Two tissue-based comprehensive genome profiling (CGP) tests (FoundationOne® CDx and OncoGuideTM NCC Oncopanel System) have been introduced into daily clinical practice since June 2019. Currently the CGP test for patients with advanced solid tumor which gets refractory to standard therapies or for which no standard therapy exists are covered by national health insurance system of Japan. Since both CGP tests require at least 20% of tumor cell contents in the specimen, patients whose tissue sample does not meet this criteria cannot undergo tissue-based CGP test. Alternatively, they can choose blood-based CGP test (liquid biopsy) since August 2021. Liquid biopsy has several advantages over tissue-based CGP but cannot simply replace the role of tissue-based CGP, due to the risk of false negative results. A new tissue-based CGP test (ACTOnco+, ACT Genomics Co., Ltd, Taipei, Taiwan) has been developed to accommodate the patients who cannot undergo a tissue-based CGP test due to low tumor cell contents. We aimed to test the feasibility of ACTOnco+ panel in daily clinical practice. This is a prospective observational study (IRB approval number, R2939). Patients who undergo a CGP tests under insurance system (insurance panel) and whose tissue samples have enough volume to submit an ACTOnco+ panel are eligible. Concordance rate of detected variants and turnaround time are compared between two panels. Ten patients have been enrolled in this study. Patients´ enrollment has been already completed. The characteristics of the 10 cases are as follows, age ranged between 41 to 78 years (mean 61.7, median 65.5), there were four males and six females, and the cancer types were three pancreatobiliary cancer, three gastric cancer, two gynecologic cancer, one malignant melanoma, and one bone tumor. The final results will be reported in the meeting.